# Clinipace

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clinipace

- Industry: Pharmaceuticals
- Headquarters: Morrisville, US
- Website: www.clinipace.com
- Total disclosed funding: $36M
- Latest round: Series D (Jan 2, 2015)
- Investors on record: 9

## About

Clinipace Inc. is a global Contract Research Organization (CRO) that delivers patient-centric clinical trial solutions across multiple therapeutic areas, streamlining the clinical development process for biopharma clients.Founded in 2003 by Jeff Williams, Clinipace Inc. is headquartered in Morrisville, US. The company operates as a standalone entity and has completed a total of 13 deals. The most recent funding round was a VENTURE DEBT round in October 2019, raising USD 4.16 mn, contributing to a total of USD 3.8 mn raised to date.Clinipace's flagship service, Caidya®, is a full-service CRO that specializes in patient-focused clinical trials for oncology, rare diseases, dermatology, and cardiovascular health. It offers comprehensive services including clinical development, regulatory affairs, and data management to ensure efficient clinical trial execution across over 40 countries, addressing diverse patient populations.Caidya generates revenue from service contracts with biopharma clients in clinical development. Its transactional model features partnerships with tailored solutions, incorporating project-based fees and ongoing service agreements. Revenue is supported by full-service trial management and specialized regulatory support, often linked to milestone payments as projects progress, fostering stable client relationships.Clinipace is focusing on the expansion of its service offerings and geographic reach, with plans to introduce new products aimed at enhancing clinical trial management by early 2024. With the funds raised in October 2019, amounting to USD 4.16 mn, Clinipace aims to bolster its operational capacity and explore new market opportunities, particularly in regions that require specialized clinical trial expertise. This strategic funding will support the development and implementation of innovative methodologies to adapt to evolving client needs.

## Funding rounds

- Series D, Jan 2, 2015, $18M — Petra Capital Partners, Harbert Management, Hatteras Venture Partners, Virgo Investment Group, Crestline Investments, Morgan Stanley Expansion Capital, Mario Family Partners
- Series C, Sep 23, 2011, $16M — BPEA Private Equity, Hatteras Venture Partners, Morgan Stanley Expansion Capital
- Series B, Dec 27, 2007, $2.6M — BPEA Private Equity, Hatteras Venture Partners, Emergent Growth Fund

## Investors

- BPEA Private Equity (https://capitalatlas.ai/funds/bpea-private-equity) — Series B, Series C
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series B, Series C, Series D
- Emergent Growth Fund — Series B
- Morgan Stanley Expansion Capital (https://capitalatlas.ai/funds/morgan-stanley-expansion-capital) — Series C, Series D
- Petra Capital Partners (https://capitalatlas.ai/funds/petra-capital-partners) — Series D
- Harbert Management (https://capitalatlas.ai/funds/harbert-management) — Series D
- Virgo Investment Group (https://capitalatlas.ai/funds/virgo-investment-group) — Series D
- Crestline Investments — Series D
- Mario Family Partners — Series D